Comparing the current results to its competitors, Fibrobiologics Inc reported Revenue decrease in the 2 quarter 2026 year on year by 0 %, despite the revenue increase by the most of its competitors of 25.72 %, recorded in the same quarter.
Fibrobiologics Inc , slower than the average decrease reported by the company's competitors of -21.04 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -21.04 %
Fibrobiologics Inc 's Comment on Competition and Industry Peers
The company operates in a competitive landscape that includes firms developing therapies for degenerative disc disease and cartilage repair. Competitors identified include Mesoblast Limited, Aesculap Implant Systems, LLC, Novartis AG, Pfizer Inc., Eli Lilly and Company, DiscGenics, Inc., Spine BioPharma, Inc., and Ferring B.V. In July 2021, Aesculap Implant Systems, LLC announced long-term results from its pivotal trial for the activl® Artificial Disc. The biotechnology and pharmaceutical industries are characterized by rapid technological advancements, intense competition, and an emphasis on proprietary and novel products. Competitors have developed or are developing products and processes that compete with the company's product candidates and existing or future therapies.
September 10, 2025
In the ever-evolving landscape of pharmaceutical sciences, innovation is the lifeblood that propels us toward groundbreaking treatments and therapies. FibroBiologics Inc., a trailblazer in regenerative medicine, has recently made significant strides with its avant-garde Bone Marrow Organoid platform, a development that stands to transform the approach to cancer and immune-related diseases.The recent pilot studies conducted by the company have reported promising results, affirming the potential of their Bone Marrow Organoid technology as a viable candidate for clinical translation. This changing tide marks not just a momentary achievement but represents a crucial step in the journey toward pre-Investigational...
2seventy Bio Inc operates on a business model centered around the development and commercialization of innovative genetic therapies. They strive to harness the power of biotechnology to address complex diseases and improve patient outcomes. By advancing their proprietary gene delivery technologies and collaborating with industry partners, they aim to create scalable treatments that revolutionize the field of genetic medicine.
Longeveron Inc's business model involves the development and commercialization of regenerative medicine products using mesenchymal stem cells for various medical conditions.
International Stem Cell Corporation Share Performance
+139.29%
This Year
International Stem Cell Corporation
Profile
International Stem Cell Corporation is a biotechnology company that focuses on developing and commercializing stem cell-based therapeutic products. They utilize their unique technology to derive unlimited amounts of pluripotent stem cells, enabling them to create therapeutics for various medical conditions.
Intrusion Inc's business model revolves around providing advanced cybersecurity solutions to protect organizations from various threats such as advanced persistent threats, zero-day attacks, and network breaches. They offer a suite of products and services including network monitoring, threat intelligence, and vulnerability management to help their clients safeguard their critical data and infrastructure.
ImmIx Biopharma Inc is a biotechnology company that focuses on developing novel therapeutics for the treatment of cancer. Their business model involves conducting extensive research and development to discover and optimize drug candidates, followed by preclinical and clinical testing to assess their safety and effectiveness. They aim to collaborate with pharmaceutical companies or seek licensing agreements to further develop and commercialize their biopharmaceutical products.
Sources:
Fibrobiologics Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Fibrobiologics Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
